Skip to content

Edward B. Garon

University of California, Los Angeles

3 papers in the Anchorcite directory, published between 2015 and 2018, cited 20,966 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience · 2015 · 7,918 citations

    Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an…

  2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations

    BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…

  3. Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations

    BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…

Metadata from OpenAlex (CC0).